Why the study?
Does continued in-hospital use of ACEi/ARB reduce mortality and ICU admission rates in hypertensive COVID-19 patients?
Does continued in-hospital use of ACEi/ARB reduce mortality and ICU admission rates in hypertensive COVID-19 patients?
Continued use of ACEi/ARBs during hospitalization for COVID-19 in hypertensive patients is associated with significantly lower mortality and ICU admission rates compared to discontinuation.
Answers are grounded in this paper and cite their sources.
Associated with lower mortality in hypertensive COVID-19 patients; hypothesis-generating pending randomized confirmation.
BACKGROUND: This study investigated continued and discontinued use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) during hospitalization of 614 hypertensive laboratory-confirmed COVID-19 patients. METHODS: Demographics, comorbidities, vital signs, laboratory data, and ACEi/ARB usage were analyzed. To account for confounders, patients were substratified by whether they developed hypotension and acute kidney injury (AKI) during the index hospitalization. RESULTS: Mortality (22% vs 17%, P > .05) and intensive care unit (ICU) admission (26% vs 12%, P > .05) rates were not significantly different between non-ACEi/ARB and ACEi/ARB groups. However, patients who continued ACEi/ARBs in the hospital had a markedly lower ICU admission rate (12% vs 26%; P = .001; odds ratio [OR] = 0.347; 95% confidence interval [CI], .187-.643) and mortality rate (6% vs 28%; P = .001; OR = 0.215; 95% CI, .101-.455) compared to patients who discontinued ACEi/ARB. The odds ratio for mortality remained significantly lower after accounting for development of hypotension or AKI. CONCLUSIONS: These findings suggest that continued ACEi/ARB use in hypertensive COVID-19 patients yields better clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Lam et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: